Menu
Not yet recruiting NCT06741501

Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy

No phase Interventional Gastric Cancer Reflux Esophagitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: "C" Single Flap Plasty Reconstruction, Normal Reconstruction.
Who it may be relevant to
Registry conditions: Gastric Cancer, Reflux Esophagitis. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Laparoscopic Proximal Gastrectomy with "C" Single Flap Plasty Reconstruction for Upper-Third Gastric Cancer: a Randomized Clinical Trial.

Overview

The incidence of proximal gastric cancer has increased significantly in recent years. This may be due to weight gain, alcohol consumption, gastroesophageal reflux disease (GERD), and precancerous lesions. With a deeper understanding of the pattern of lymph node metastasis and the emergence of anti-reflux procedures, proximal gastrectomy has gradually received clinical attention. For early-stage upper gastric cancer and esophagogastric combination cancer cases that are expected to have a good prognosis, the ideal surgical procedure should be to preserve the distal stomach to improve the quality of life and to choose a reasonable digestive tract reconstruction method to prevent reflux. The anti-reflux effect of various proximal gastrectomy digestive tract reconstruction methods and the advantages and disadvantages of various surgical procedures are controversial, and the recognized ideal reconstruction method has not yet been established. Therefore, we propose a reconstruction called the "C" Single Flap Plasty Reconstruction. This study aimed to investigate the efficacy and safety of proximal gastrectomy combined with "C" Single Flap Plasty Reconstruction in the treatment of gastric cancer.

Interventions

  • Procedure "C" Single Flap Plasty Reconstruction
    1\. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high "C"-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior e
  • Procedure Normal Reconstruction
    1\. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.

Primary outcome measures

  • incidence of reflux esophagitis [Time frame: 6 months after surgery]
Secondary outcome measures (1)
  • incidence of anastomotic leakage [Time frame: 30 days after surgery]

Eligibility criteria

Inclusion criteria

  • Age between 18-80 years old, male or female;
  • Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer: Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) according to the eighth edition of the AJCC ;
  • No distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal CT;
  • ASA grade 1-3;
  • Patients without contraindications to surgery;
  • Patients and their families voluntarily signed the informed consent form and participated in the study;

Exclusion criteria

  • Patients diagnosed with primary tumors or distant metastasis;
  • Patients whose tumor is located in the greater curvature side of the stomach;
  • Patients with coagulation dysfunction that could not be corrected;
  • Patients who were diagnosed with viral hepatitis and cirrhosis;
  • Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin;
  • Patients with organ failure such as heart, lung, liver, brain, and kidney failure;
  • Patients with ascites or cachexia preoperatively in poor general conditions;
  • Patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).
  • Patients refusing to sign the informed consent of the study;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Northern Jiangsu People's Hospital — Yangzhou

Identifiers

NCT: NCT06741501 · northernjiangsu007

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗